Clinical trials: sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumors
A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation and dose expansion, and cohort-expansion phase Ib/II clinical study to evaluate the safety and antitumor efficacy of SYH2051 in combination with Irinotecan Hydrochloride Liposome…
- Trial name
- NCT07911579
- Testing
- SYH2051, Irinotecan Hydrochloride Liposome.
- Where
- China
- Volunteers
- 154 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Major Depressive Disorder (MDD)
The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.
- Trial name
- NCT06827431
- Testing
- Ammoxetine, Sertraline
- Where
- 2 sites in China
- Volunteers
- 786 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Overweight or Obesity
A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants
To evaluate the safety and tolerability of single dose and multiple doses of SYH2082 Injection in healthy participants.
- Trial name
- NCT07532655
- Testing
- SYH2082 Injection
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Acromegaly
A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly
This trial is a phase II clinical trial to evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of octreotide long-acting injection in patients with acromegaly.
- Trial name
- NCT07814651
- Testing
- SYHX2008, Sandostatin LAR
- Where
- China
- Volunteers
- 78 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
HER2-Negative Advanced Breast Cancer
A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer
This is a randomized, open-label, multicenter Phase Ⅲ clinical trial designed to evaluate the efficacy and safety of HB1801 versus Taxotere® in patients with HER2-negative advanced breast cancer.
- Trial name
- NCT07805135
- Testing
- HB1801, Docetaxel (Taxotere®)
- Volunteers
- 430 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Influenza
A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of SYH2085 tablets compared with placebo in Chinese adult participants with uncomplicated influenza.
- Trial name
- NCT07798193
- Testing
- SYH2085
- Volunteers
- 213 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Myasthenia Gravis
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
This study is a single-arm, open, 2-stage (dose-escalation phase and dose-expansion phase), multi-center, phase I clinical trial to evaluate the safety and tolerance of SYS6020 injection in the participants with refractory…
- Trial name
- NCT06688435
- Testing
- SYS6020 injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants
Evaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Participants.
Evaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine hydrochloride Enteric-coated Tablets in Healthy Participants.The study is composed of 2 parts.
- Trial name
- NCT07756996
- Testing
- Ammoxetine hydrochloride Enteric-coated Tablets(new formulation), Ammoxetine hydrochloride Enteric-coated Tablets(Phase III formulation)
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants, Participants With Mild Hepatic Impairment
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function
Use these resources to provide understandable information about this study to patients, families, and health care providers:This study is a multi-center, non-randomized, open-label, parallel-group, multiple-dose Phase I clinical…
- Conditions
- Healthy Participants, Participants With Mild Hepatic Impairment, Participants With Moderate Hepatic Impairment
- Trial name
- NCT07694843
- Testing
- ammoxetine hydrochloride enteric-coated tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants, Participants With Moderate Renal Impairment
A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function
This study is a single-center, non-randomized, open-label, parallel-group, multiple-dose Phase I clinical trial evaluating the pharmacokinetic characteristics of ammoxetine hydrochloride enteric-coated tablets in participants…
- Trial name
- NCT07694869
- Testing
- ammoxetine hydrochloride enteric-coated tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Malignant Tumors
SYH2095 for Advanced Malignant Tumors: Phase I Study
This is an open-label, multicenter Phase 1 first-in-human trial of SYH2095, a selective KAT6A/B inhibitor. The trail contains two segments: Part 1A dose escalation and Part 2A cohort expansion.
- Trial name
- SYH2095-001 (NCT07692776)
- Testing
- SYH2095
- Where
- China
- Volunteers
- 140 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Epithelioid Hemangioendothelioma
A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma
A Single-Arm, Non-Randomized, Open-Label Phase 2 Study of Nab-Sirolimus in Patients with Progressive or Symptomatic Epithelioid Hemangioendothelioma.
- Trial name
- NCT07684287
- Testing
- Sirolimus for injection (Albumin-bound)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Diagnosed With Acromegaly, Currently in the Active Stage of the Disease
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.
- Trial name
- NCT07623824
- Testing
- SYHX2008, Sandostatin LAR®
- Volunteers
- 154 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Gastroenteropancreatic Neuroendocrine Tumors
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
There is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with poor prognostic factors.
- Trial name
- NCT07165886
- Testing
- Sirolimus for injection (albumin bound), Octreotide long-acting injection, Everolimus
- Where
- China
- Volunteers
- 298 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants
A Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects
This study is a single-dose, randomized, open-label, three-sequence, three-period crossover clinical trial to evaluate the effect of high-fat and low-fat meals on the pharmacokinetics of ammoxetine hydrochloride enteric-coated…
- Trial name
- NCT07508462
- Testing
- Ammoxetine hydrochloride enteric-coated tablets
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants
Food-effect Study of Ammoxetine Hydrochloride Enteric-coated Tablets
This study is a single-center, randomized, open-label, two-period crossover design to evaluate the effect of food on the pharmacokinetic profile of ammoxetine hydrochloride enteric-coated tablets.
- Trial name
- NCT07508501
- Testing
- Ammoxetine hydrochloride enteric-coated tablets
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Chronic Obstructive Pulmonary Disease
A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to Severe…
- Trial name
- NCT07418736
- Testing
- CM326 dose 1, CM326 dose 2
- Where
- China
- Volunteers
- 318 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants
A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085
Randomized, double-blind and placebo-controlled study to assess the safety, tolerability and pharmacokinetics of single ascending doses of SYH2085 and its food effect in China healthy adult participants.
- Trial name
- NCT07412353
- Testing
- SYH2085
- Where
- China
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer
This trial is an open-label, dose-escalation, and randomized controlled Phase Ib/II clinical study for second-line treatment in participants with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT07282509
- Testing
- HA131, Enlonstobart Injection, Pembrolizumab Injection
- Volunteers
- 116 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumors
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
This study adopts a multi-center, open-label, non-randomized trial design. It plans to enroll patients with Advanced solid tumor.
- Trial name
- NCT07241936
- Testing
- sirolimus (albumin-bound), DP303c, SYS6043
- Where
- China
- Volunteers
- 444 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.